CoChat

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

Open access
Chang-Yew Leow, C, Gerondakis, S, Spencer, A · 2013 · Blood Cancer Journal
Cited by 62

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade is common in a wide array of malignancies, including multiple myeloma (MM), making it an appealing candidate for the development of novel targeted therapies. In this review, we explore our current understanding of the Ras/MAPK pathway and its role in MM. Additionally, we summarise the current status of small molecule inhibitors of MEK under clinical evaluation, and discuss future approaches required to optimise their use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2013.1

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 13 references

Cited by

See all 62

Metadata

Authors
Chang-Yew Leow, C., Gerondakis, S., & Spencer, A.
Venue
Blood Cancer Journal
Published
2013-03-22
Volume
3
Issue
3
Pages
e105-e105
ISSN
2044-5385 (ISSN-L)
OpenAlex
W1968036059
Cited by
62
References
13
FWCI
4.69
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. https://app.cochat.ai/papers/10.1038/bcj.2013.1
The paper
Chang-Yew Leow, C., Gerondakis, S., & Spencer, A. (2013). MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer Journal. https://doi.org/10.1038/bcj.2013.1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.